The first fifty years of the Connecticut Tumor Registry (1935Registry ( -1985 have seen unprecedented progress in the collection of standardized data on cancer patients and in the processing of these data, from paper documents to punch cards and magnetic tapes. The need for collecting such information was first recognized, in the early 1930s, by a group of physicians, health professionals, and laymen in New Haven who observed alarming increases in cancer rates and poor survival of cancer patients in this city. This paper recalls the growth and development of the registry and the role played by the Connecticut legislature, the State Medical Society, the Connecticut Department of Health, and the National Cancer Institute in this process. For half a century, the registry has provided assistance to practitioners, hospitals, and research scientists, not only in Connecticut but across the country and around the world. By making available reliable data on incidence and survival, the registry has played a key role in patient management, clinical trials, and etiologic studies. It has also demonstrated the value and served as an exemplary model of a population-based registry.
the State Board of Health "to make investigation concerning cancer, the prevention and treatment thereof and the mortality therefrom... ." The legislature also allocated $10,000 in 1935 to enable the State Board of Health to carry out a cancer program in Connecticut, this money to be used from July 1, 1935, to June 30, 1937 . In addition, the sum of $6,683.00 was allotted in 1936 by the federal government under Title VI, Public Health Service Section of the Social Security Act, to be used in cancer activities [4] .
With [5] .
Although congressional attention to the issue of cancer control in the U.S.A. was reported as early as 1927, the National Cancer Institute Act (Public Law 244) was not signed until ten years later, in 1937, by President Franklin D. Roosevelt, to set in motion a federal commitment to cancer control [6] .
The new Division of Cancer Research in the Connecticut State Department of Health worked closely with the State Medical Society's Tumor Study Committee which, in 1949, adopted its current name, the Cancer Coordinating Committee. In the years between 1935 and 1941, it carried out analyses of mortality statistics, assisted in the establishment of tumor clinics, and facilitated legislative activities.
The 1935 legislation authorized the State Department of Health to investigate cancer and set aside money to pay hospitals for reporting. This had the effect of initiating a comprehensive statewide cancer reporting system. Money was deemed more important than a reporting requirement. The funds made available sufficed to support a registry staff in the Health Department and, equally important, to pay the salary of a tumor clinic secretary in each Connecticut hospital. The sponsors were primarily interested in patient survival data; incidence data were secondary. This is not surprising; cancer epidemiology was then in its infancy. There were no populationbased cancer registries, and the first cancer morbidity survey undertaken by the National Cancer Institute (NCI) was just getting under way [7] . The first case-control studies on smoking and lung cancer would not be reported for another ten years [8, 9] . The sponsors probably realized that direct support for secretaries to service the hospital clinics and tumor registry ensured that someone in each of the 28 to 30 hospitals then in existence in Connecticut would be on hand to take care of the records and do the necessary patient follow-up. The key reporting unit was the hospital, not the individual physician. So long as there were direct dealings between the hospitals and the cancer registry, concern about protecting the confidentiality of patients' records was not a major issue at that time.
In 1941, a team from the State Division of Cancer Research visited each participating hospital and made abstracts of the records of each cancer patient admitted to the hospital, beginning with January 1935. During these visits, the tumor clinics' secretaries were trained to carry out the case registration functions. The key element which made the tumor registry a going concern was the provision of financial support for each hospital's tumor clinic secretary. By December 1942, 22 hospitals, comprising over 90 percent of the hospital beds in Connecticut, were reporting. The remaining hospitals were contacted thereafter, and arrangements were made to incorporate them into the new registry system [10] .
A reporting system that covered hospitalized patients only would have missed that fraction of patients not admitted to hospitals. This made it necessary to match all Connecticut death certificates which mentioned cancer against the case reports from hospitals in order to ascertain the fraction of deaths not previously reported as cases. From its inception, the registry routinely secured copies of death certificates from the Bureau of Vital Statistics. Over the years, the proportion of cancer deaths not previously reported as cases fell from a high 37 percent in the first six years of the registry to 1.3 percent in the late 1970s [11, 12] .
At the registry's inception, the plan was to report all cases of cancer first diagnosed on and after "By 1949, a substantial backlog of records awaited processing, and physicians were requesting assistance for ad hoc studies. This situation was further complicated by staff shortages. There was a need to move from the registry's development phase to the establishment of data processing routines on a current basis. Ms.MacDonald left the registry to accept an appointment as Professor of Epidemiology at M.D. Anderson Hospital in Texas. Prior to that time, I had no direct involvement in the management of the tumor registry, although I was aware of its activities and of the support it was getting from the State Medical Society. I remember that Dr. Griswold attended regularly the meetings of the State Medical Society's Tumor Study Committee, perhaps as often as once a month or every other month. I also recall the names of two physicians who were key participants in State Medical Society committees and keenly interested in working with the registry data-Drs. E.J. Ottenheimer and A.W. Oughterson. They were particularly interested in the survival of patients with cancer of the rectum [13] . This was a time when a more aggressive approach to rectal cancers, including dissection of the anus and rectum with colostomy, was being introduced. They were seeking evidence from registry data for improved survival of patients with rectal cancer.
"When Ms. MacDonald left the registry, the Commissioner of Health, Dr. Stanley Osborn, asked me to confer with Dr. Griswold and advise him on recruiting a replacement. Data management was the main concern. Dr. Griswold and I needed advice from someone experienced in large-scale processing of cancer patient data. The NCI's second national cancer morbidity survey of 1947-1948, headed by Harold Dorn, Ph.D., [14] was nearing completion, and we approached him for assistance. Dr. Dorn, Chief of the Biometric Section, NCI, sent Dr. Sidney J. Cutler, analytic statistician in his section, to review the registry's operations. One should remember that the postwar years were those of transition in data management, ranging from hand files, keysort cards, punch cards, and the use of printing tabulators. Dr. Cutler provided sound advice and, in effect, ushered in the era of data management. Dr. Earl Pollack was recruited from the New York State Department of Health to replace Ms. MacDonald and, with the assistance of Charles S. Wilder, he implemented Dr. Cutler's recommendations and brought the data management and processing elements of the registry under good control.
"In 1952, Dr. Dorn recruited me as his replacement at the NCI Biometry Branch, so I became head of a consulting unit which I had earlier dealt with while acting in a different capacity. This sequence of events laid the foundation for the sustained collaboration between the Connecticut Tumor Registry and the NCI in later years.
"With the completion of the data management phase, it became time to focus attention on data analysis. Dr. Cutler, who continued to serve as a consultant to the registry, and I participated in the preparation of a monograph entitled Cancer in Connecticut: [1935] [1936] [1937] [1938] [1939] [1940] [1941] [1942] [1943] [1944] [1945] [1946] [1947] [1948] [1949] [1950] [1951] , which was published in 1955 [15] . This publication of registry data, based on a standardized format for tabulations, resulted from many discussions with and suggestions by Drs. Griswold [17] .
"The history of the Connecticut Tumor Registry was profoundly influenced by an event that took place at NCI. The research program in cancer treatment under the auspices of the Cancer Chemotherapy National Service Center (CCNSC) needed baseline data on patient survival to supplement data generated by clinical trials in evaluating the effects of new therapies. No systematic national data on site-specific cancer patient survival existed as of 1955. Dr. Michael Shimkin, Chief of Biometry Branch, NCI, proposed that a group of hospital-based registries and some populationbased registries (including Connecticut) prepare a standard set of tabulations and report the findings at the 1956 National Cancer Conference in Detroit. The presentation of data was judged a success, leading to the proposal that the registries report their updated findings at the 1960 National Cancer Conference in Minneapolis. At meeting of registry representatives, I proposed that the tabulations be replaced by a set of uniform punch cards. This led to the formation of the End Results Group (ERG), which not only reported their findings at Minneapolis but stayed together to publish their findings for many years thereafter. The Connecticut data played an important role in establishing the baseline experience of all cancer patients for comparison with the results from the specialized, tertiary care institutions. In these early years, the registry's participation in the NCI-sponsored End Results Group was subsidized for out-of-pocket costs by the Connecticut Department of Health. The Connecticut data were also valuable for delineating trends in survival rates in Connecticut and California (NCI Monograph number 6) [18] .
"Following the adoption of uniform punch cards for recording data, the staff in the Connecticut registry made important contributions to the ERG procedures manual by providing instructions for coding, editing, consistency checks, and other data management operations. "In the late 1 950s, Dr. Franklin Foote was Commissioner of Health. The staff of the registry then included Dr. Eisenberg, Director of the Division of Cancer and Chronic Diseases; R. Greenberg, Chief Statistician; Jack R. Keough, Registry Director; and Patricia Campbell, Tumor Registry Supervisor.
"The Connecticut registry indirectly influenced the interpretation of data from the clinical trials of leukemia chemotherapy. Dr. Cutler repeatedly brought to the attention of Dr. Zubrod, at the NCI, and other clinical investigators, that the results of clinical trials describing dramatic treatment effects were not being reflected in the experience of the general population as observed in the Connecticut registry. Continued reference to the Connecticut data tended to moderate the interpretation of the clinical trial findings.
"In addition to its participation in ERG, the Connecticut registry was a charter contributor to the first volume of Cancer Incidence in Five Continents [19] and has provided current data in all subsequent editions. Dr. Eisenberg was a member of the editorial committee that advised on the format for the initial publication.
"Standard actuarial procedures, described by Berkson and Gage [20] [7, 14] , but these were certainly'inferior to the Connecticut data. The Connecticut data clearly indicated the major changes in risk, the rise in male and female lung cancer, the decline in stomach cancer, etc. Given the predominantly white population of Connecticut, the registry did not supply useful data on blacks. In the early years of the registry, no examples can be cited of its ability to detect changes in risk for specific site-histology complexes. The latter had to await a more refined morphological classification of tumors contained in the Standardized Nomenclature of Pathology (SNOP) and adapted for tumor registries by an American Cancer Society committee [26] . However [29] . She was assisted by J.T. Flannery, who joined the registry in 1962 and became director in 1975. His management of the registry has remained, until this day, an example of efficiency and dedicated effort. "In the late 1960s, a data management problem arose to complicate the effective participation of the Connecticut registry in the End Results Group. The state government committed itself to the establishment of a centralized computer center to service all departments of state government. Even though the NCI contract covered all data processing costs, the Connecticut registry was prevented from establishing its own computer unit. While the difficulties caused by this inflexible computer processing arrangement have improved over time, the Connecticut Tumor Registry does not, to date, have it own computer facilities.
"Early in the 1970s a budget crisis in the Connecticut state government intervened to threaten further supply of data to the End Results Group. To cope with this deficit, the governor proposed eliminating payments to the hospital tumor registry secretaries and making the reporting of cancer cases compulsory, thus shifting the costs to the individual hospitals. A statute was passed mandating that cancer become a reportable disease effective March 23, 1971 [30] . This turn of events posed a dilemma to the NCI. Connecticut's participation in the End Results Group met important national goals. Experience elsewhere had shown that loss of funding for essential support services inevitably led to the demise of a cancer registry. The risk to the End Result Group program, through failure to support the hospital tumor registry activities in Connecticut, was unacceptable to the NCI, which had a substantial investment in the ERG. Therefore, the NCI increased its support to the Connecticut registry, which now had the legal right to require that cancer be reported to the State Health Department. It is worthwhile noting that at this time, on the national scene, the 92nd Congress of the U.S. passed a bill (H.R. 8343, H.R. 10681, S 1828) in 1971 to establish a National Cancer Authority in order to conquer cancer at the earliet possible date. This bill was entitled 'The National Cancer Attack Act of 1971' [31] .
"Up to 1972, the relationship between the registry and NCI had been through participation in the End Results Group. Before that time, the NCI had two distinct programs for the collection of incidence and patient survival data. The End Results Group supplied the survival data, while the incidence data had been collected through cancer morbidity surveys. With the completion of the third national cancer morbidity survey covering the years 1969-71 [32] , it was obvious that the cancer morbidity survey approach was inefficient and that it would be preferable to establish a network of population-based cancer registries. The Connecticut Tumor Registry became a participant in this network, which was established at the NCI in 1972 under the title 'Surveillance, Epidemiology, and End Results (SEER) Program.' "A problem which reoccurred during this period was the inability of the Connecticut Tumor Registry to recruit research staff. This situation called for other arrangements. There was a need to combine the strong Connecticut registry capabilities in data management with those of an institution with a good research base. In Connecticut, the two obvious candidates were the University of Connecticut School of Medicine and Yale University. Yale was judged superior because of its ability to identify people who could conduct epidemiologic research and who were in contact with physicians in the state. There ensued exploratory negotiations concerning the feasibility of establishing a Connecticut Cancer Epidemiology Unit (CCEU) at the Yale University Department of Epidemiology and Public Health. The outcome was that the work of the Connecticut registry and its research arm, the CCEU, was supported by two NCI contracts, one with the State Department of Health and the other with Yale University. Dr. J. Wister Meigs was appointed the first director of CCEU in 1974 [33] . In a recent paper, he described the role of the Connecticut Tumor Registry during its fifty years of service in assisting a large number of cancer epidemiologists, both at home and abroad [34] . [35] . Following a survey of 1,572 records from the Connecticut Tumor Registry, she also evaluated the usefulness of epidemiologic data currently being collected on patients' occupation/industry, smoking habits, and family history of cancer. Criteria for usefulness of these data were based on their potential for standardization and statistical analysis [36] . In this study, the rapidity with which hospitals report cancer cases to the Connecticut registry was also investigated. The study found that 47.5 percent of cases had been reported to the Connecticut Tumor Registry within three months of diagnosis, 77.5 percent within six months, and 97.5 percent within one year. There was no evidence that hospital size played a major role in the rapidity of reporting, although small hospitals had a greater number of cases reported within three and six months than larger hospitals.
While the Connecticut Tumor Registry was dependent for data on the hospital tumor clinic secretaries in the early years of its development, it now depends on the hospital tumor registrars to provide rapidly an increased amount of data to the registry. Registrars, who are presently certified by the National Tumor Registrars Association, are well trained and capable of performing a wide variety of cancer data management skills [37] . They play an important role in maintaining the quality and completeness of data in the Connecticut Tumor Registry.
Dr. D. Janerich became director of the CCEU and Medical Director of the Connecticut Tumor Registry in 1985. He established, in the Department of Epidemiology and Public Health at Yale, the first Cancer Control Research Unit (CCRU) for Connecticut, supported by the NCI, and the CCEU research arm of the tumor registry was moved from New Haven to Hartford.
This new CCRU endeavor is developed around the Connecticut Tumor Registry, which will require uninterrupted financial support. It will bring together investigators from Yale University, the University of Connecticut, and the Connecticut State Department of Health Services in an effort to devise and apply methods of prevention for various types of cancer. Among a number of epidemiologic, clinical, and laboratory projects, a statewide study will be undertaken during the 1986-1991 period aimed at eradicating invasive cervical cancer, a disease which should be preventable at this time [38] .
This multidisciplinary effort to prevent cancer will require the collaboration of many investigators whose various skills will increase our understanding of the biology and control of this disease.
A renewed emphasis on cancer control, both at home and abroad, will be featured in the years ahead. These preventive programs will continue to utilize the resources of the Connecticut Tumor Registry and add another chapter to its first fifty years of valuable service.
